Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous belimumab in pediatric systemic lupus erythematosus: pharmacokinetics and safety
2018-004645-16Phase 2Active
- Sponsor
- GSK
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoint: Observed belimumab concentrations at Week 12. Started Sep 2019; status: active.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-004645-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004645-16.